Trials / Completed
CompletedNCT00250471
PROTECT-TIMI 30 Trial
A Randomized Trial to Evaluate the Relative Protection Against Post-PCI Microvascular Dysfunction and Post-PCI Ischemia Among Anti-Platelet and Anti-Thrombotic Agents
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 900 (planned)
- Sponsor
- Millennium Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this study was to compare the efficacy and safety of bivalirudin to eptifibatide (with or without unfractionated heparin or enoxaparin)given to subjects at high risk for heart attack and other cardiovascular complications who will undergo surgery to open up blocked arteries in the heart.
Detailed description
Platelet inhibitor drugs
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Percutaneous Coronary Intervention (PCI) |
Timeline
- Start date
- 2003-05-01
- Completion
- 2004-09-01
- First posted
- 2005-11-08
- Last updated
- 2005-11-08
Source: ClinicalTrials.gov record NCT00250471. Inclusion in this directory is not an endorsement.